Format

Send to

Choose Destination
Antiviral Res. 2019 Apr 8;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. [Epub ahead of print]

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Author information

1
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: jbeigel@niaid.nih.gov.
2
(b)Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
3
Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), Department of Health and Human Services (HHS), Washington, DC, USA.
4
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
5
Division of Antiviral Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S Food and Drug Administration, Silver Spring, MD, USA.
6
Gillings School of Global Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.

Abstract

The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.

KEYWORDS:

Antiviral therapy; Coronavirus; Host-directed therapeutics; Influenza; Respiratory syncytial virus

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center